文献速递湿疹皮炎与荨麻疹

老年人在特应性皮炎系统治疗随机临床试验中的代表性:一项系统综述

Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review.
PubMed 文献 · JAMA Dermatol · 2020-01-01

本系统综述检索至2019年11月7日,纳入32项针对成人特应性皮炎系统免疫调节治疗的随机临床试验(共4547例参与者)。结果显示老年人代表性不足:仅31%的试验纳入65岁及以上成人,且无试验报告针对老年人的分层安全性或有效性数据。

要点

  • 老年人(≥65岁)在特应性皮炎系统治疗随机试验中代表性低,仅31%的试验纳入。
  • 仅7项试验报告了65岁及以上参与者比例,汇总为4%(112/2964),均评估度普利尤单抗。
  • 无试验报告针对老年人的分层安全性或有效性数据,存在证据缺口。

核心结论

  • 老年人(≥65岁)在特应性皮炎系统治疗随机临床试验中代表性不足,导致缺乏支持其安全临床使用的证据。

研究设计与样本

  • 系统综述检索Cochrane Central Register of Controlled Trials、Embase、MEDLINE及ClinicalTrials.gov,从建库至2019年11月7日,纳入成人特应性皮炎系统免疫调节治疗的随机临床试验。
  • 共纳入32项试验,4547例参与者;参与者平均(SD)年龄34.4(5.4)岁,每项试验参与者中位数44例(范围10-740)。

主要发现

  • 11项试验(34%)报告了明确的上限年龄,范围为42至70岁,其中9项评估环孢素的安全性和有效性。
  • 共10项试验(31%)纳入65岁及以上成人。
  • 在7项报告65岁及以上参与者比例的试验(均评估度普利尤单抗)中,2964例参与者中112例(4%)为65岁及以上。
  • 无纳入试验报告针对老年人的分层安全性或有效性数据。

关键数值与推荐

  • 11项试验(34%)报告明确上限年龄,范围为42至70岁。
  • 10项试验(31%)纳入65岁及以上成人。
  • 7项试验报告65岁及以上参与者比例,汇总为4%(112/2964)。

临床怎么用

  • 临床医生和患者在处方特应性皮炎系统治疗时应意识到老年人证据缺口。
  • 需要纳入老年特应性皮炎患者的随机试验和观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite increasing evidence that atopic dermatitis is common in older adults, it is unclear whether the evidence base for treating atopic dermatitis with systemic therapy is generalizable to that population. Older adults are most at risk for adverse events from medications, given age-related alterations in drug metabolism, increased comorbidity, and polypharmacy. OBJECTIVE: This systematic review examines the representation of older adults in randomized clinical trials (RCTs) of systemic immunomodulatory treatments for atopic dermatitis and whether safety and efficacy data are reported specifically for older individuals. EVIDENCE REVIEW: The Cochrane Central Register of Controlled Trials, Embase, MEDLINE databases, and the ClinicalTrials.gov trial register were searched from inception (MEDLINE via Ovid, 1946; Embase via Ovid, 1974) to November 7, 2019. RCTs investigating systemic immunomodulatory treatments for adults with atopic dermatitis were included. Titles, abstracts, and full-text papers were screened, and data were extracted in duplicate. FINDINGS: A total of 32 trials with 4547 participants were reviewed. The mean (SD) age of trial participants was 34.4 (5.4) years. The median number of participants per trial was 44 (range, 10-740). Eleven trials (34%) reported explicit upper age limits ranging from 42 to 70 years of age. Most of these trials (n = 9) examined safety and effectiveness of cyclosporine. Twenty-two trials (69%) had other exclusion criteria that might disproportionately exclude older adults. In total, 10 trials (31%) included adults aged 65 years or older. Within 7 trials that reported the proportion of participants aged 65 and older (all evaluating dupilumab), 112 of 2964 participants (4%) were 65 years or older. None of the included trials reported stratified safety or effectiveness data for older adults. CONCLUSIONS AND RELEVANCE: Study results suggest that older adults are underrepresented in RCTs of systemic treatment for atopic dermatitis, resulting in a lack of evidence supporting safe clinical use for older adults. Clinicians and patients should be aware of this evidence gap when prescribing systemic therapy for atopic dermatitis. Randomized trials and observational studies that include older patients with atopic dermatitis are needed.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lam M, Zhu JW, Maqbool T, et al. Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2020. PMID: 32822481. doi:10.1001/jamadermatol.2020.2940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。